LBA56 Perioperative or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Results of the NEONAX trial, a randomized phase II AIO study

Seufferlein, T.T.SeufferleinUhl, W.W.UhlAlgül, H.H.AlgülFriess, H.H.FriessKornmann, M.M.KornmannKönig, A.O.A.O.KönigGhadimi, M.M.GhadimiGress, T.M.T.M.GressLutz, M.P.M.P.LutzWille, K.K.WilleEttrich, T.J.T.J.Ettrich2021-12-012021-12-012021https://resolver.sub.uni-goettingen.de/purl?gro-2/94675enhttps://www.elsevier.com/tdm/userlicense/1.0/LBA56 Perioperative or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Results of the NEONAX trial, a randomized phase II AIO studyjournal_article10.1016/j.annonc.2021.08.2136S0923753421044409